Breast Cancer Research in New Zealand partnership

Dr Annette Lasham
The University of Auckland
Funder(s): HRC, Breast Cancer Cure, Breast Cancer Foundation NZ
Validation of a liquid biopsy to predict recurrence in NZ breast cancer patients
$244,095
18 months

Lay summary

Early detection of breast cancer recurrence is critical for saving lives. We have identified two molecules, found in the blood of 250 patients at the time of surgery for breast cancer, that were very good at predicting which of these women would have a relapse before 5 years. We now want to validate these molecules on a new group of 400 NZ breast cancer patients, to see whether these molecules could be used as a blood test to predict disease recurrence. We also want to see if we can combine information from this blood test with existing clinical and pathological tests, to give doctors and patients greater knowledge about their prognosis. We will use advanced statistics to determine what information to include in order to generate the best prognostic test. This information could guide treatment decisions or suggest a requirement for closer surveillance of patients following surgery for breast cancer.

Back to Funding Recipients